Atopic dermatitis (AD) is a chronic itch and inflammatory disorder of the skin that affects one in ten people. Patients suffering from severe AD eventually progress to develop asthma and allergic rhinitis, in a process known as the ''atopic march.'' Signaling between epithelial cells and innate immune cells via the cytokine thymic stromal lymphopoietin (TSLP) is thought to drive AD and the atopic march. Here, we report that epithelial cells directly communicate to cutaneous sensory neurons via TSLP to promote itch. We identify the ORAI1/NFAT calcium signaling pathway as an essential regulator of TSLP release from keratinocytes, the primary epithelial cells of the skin. TSLP then acts directly on a subset of TRPA1-positive sensory neurons to trigger robust itch behaviors. Our results support a model whereby calcium-dependent TSLP release by keratinocytes activates both primary afferent neurons and immune cells to promote inflammatory responses in the skin and airways.
INTRODUCTION
Atopic dermatitis (AD) is a chronic itch and inflammatory disorder of the skin that affects one in ten people. AD is primarily characterized by intolerable and incurable itch. Up to 70% of AD patients go on to develop asthma in a process known as the ''atopic march'' (He and Geha, 2010; Locksley, 2010; Spergel and Paller, 2003; Ziegler et al., 2013) . Numerous studies suggest that the cytokine thymic stromal lymphopoietin (TSLP) acts as a master switch that triggers both the initiation and maintenance of AD and the atopic march (Moniaga et al., 2013; Ziegler et al., 2013) . TSLP is highly expressed in human cutaneous epithelial cells in AD and bronchial epithelial cells in asthma (Jariwala et al., 2011) . Overexpression of TSLP in keratinocytes, the most prevalent cell type in the skin, triggers robust itch-evoked scratching, the development of an AD-like skin phenotype, and ultimately asthma-like lung inflammation in mice (Li et al., 2005; Ying et al., 2005; Ziegler et al., 2013) . However, the mechanisms by which TSLP triggers itch and AD remain enigmatic.
Itch is mediated by primary afferent somatosensory neurons that have cell bodies in the dorsal root ganglia (DRG) that innervate the skin and are activated by endogenous pruritogens to drive itch behaviors (Ikoma et al., 2006; McCoy et al., 2012; Ross, 2011) . Hallmarks of AD skin include robust itch sensations, increased neuronal activity, and hyperinnervation Tobin et al., 1992; Tominaga et al., 2009) . Although many studies have shown that epithelial cell-derived TSLP activates T cells, dendritic cells, and mast cells (Ziegler et al., 2013) , the role of sensory neurons in this pathway has not been studied. How does TSLP lead to sensory neuron activation to promote itch?
In vitro studies suggest that keratinocytes may directly communicate with sensory neurons via neuromodulators (Ikoma et al., 2006) . Indeed, many of the factors that keratinocytes secrete act on both immune cells and primary afferent sensory neurons (Andoh et al., 2001; Fitzsimons et al., 2001; Kanda et al., 2005; Ziegler et al., 2013) . Thus, TSLP may evoke itch behaviors directly, by activating sensory neurons, indirectly, by activating immune cells that secrete inflammatory mediators that target sensory neurons, or both. Although TSLP's action on immune cells is well characterized, its effects on sensory neurons, and the contribution of sensory neurons to TSLP-evoked atopic disease, have not been studied. Furthermore, the mechanisms regulating TSLP release by keratinocytes are unknown.
The GPCR protease-activated receptor 2 (PAR2) plays a key role in keratinocyte TSLP production. Studies have shown a correlation between PAR2 activity and TSLP expression in the skin of AD patients and in mouse models of atopic disease (Briot et al., 2009 (Briot et al., , 2010 Hovnanian, 2013) . In addition, PAR2 activation triggers robust TSLP expression in keratinocytes (Kouzaki et al., 2009; Moniaga et al., 2013) . Although there is a strong correlation between PAR2 activity and TSLP levels in the skin, virtually nothing is known about the molecular mechanisms by which PAR2 leads to TSLP expression.
Here, we sought to elucidate the mechanisms that regulate TSLP secretion and that promote TSLP-evoked itch. Our findings show that keratinocyte-derived TSLP activates sensory neurons directly to evoke itch behaviors. We define a subset of sensory neurons that require both functional TSLP receptors and the ion channel, TRPA1, to promote TSLP-evoked itch behaviors, and we identify the ORAI1/NFAT signaling pathway as a key regulator of PAR2-mediated TSLP secretion by epithelial cells.
RESULTS

TSLP Evokes Robust Itch Behaviors in Mice
To identify proteins that mediate itch transduction in somatosensory neurons, we looked for biomarkers of AD (Lee and Yu, 2011) in the mouse DRG transcriptome (Gerhold et al., 2013) . We were surprised to find expression of the TSLP receptor (TSLPR) in mouse sensory ganglia. Although studies have shown that TSLP acts on various immune cells, TSLP signaling in the nervous system has not been reported. TSLPR is a heterodimer, composed of the IL7 receptor alpha (IL7Ra) chain and a TSLPspecific receptor chain (TSLPR; also Crlf2) (Pandey et al., 2000) . Consistent with the presence of TSLPRs in sensory neu- rons, we detected both TSLPR and IL7Ra transcripts in mouse and human DRG using RT-PCR ( Figure 1A ). Somatosensory neurons mediate itch, touch, and pain. Thus, we asked if TSLP injection triggers itch and/or pain behaviors by using a mouse cheek model of itch, which permits easy distinction between these behaviors (Shimada and LaMotte, 2008) . Injection of TSLP into the cheek of wild-type mice evoked robust scratching that was not observed following vehicle injection (Figures 1B and 1C) . Wiping was never observed, indicating that TSLP triggers itch, rather than pain (Shimada and LaMotte, 2008) . Intradermal injection of TSLP has been previously shown to evoke inflammation of the skin and lung over the course of hours or days (Jessup et al., 2008) . However, we observed robust itch behaviors within 5 min of TSLP injection (latency to scratch = 4.1 ± 0.3 min).
Although immune cells play a key role in long-term TSLPevoked inflammation, whether immune cells are required for acute TSLP-triggered itch behaviors is unknown. The current model posits that TSLP acts on various immune cells to promote TH2 cell differentiation and inflammation. We thus compared TSLP-evoked itch behaviors of wild-type mice to mouse strains lacking either T and B cells (RAG1 À/À , NOD SCID) or mast cells (Kit(W-sh) ( Figures 1D and 1E ). TSLP triggered robust itch behaviors in all strains, with no significant differences between transgenic and congenic wild-type littermates. Together, these data indicate that acute TSLP-evoked itch does not specifically require lymphocytes or mast cells, nor does it require the cytokines or other products produced when these cells are activated, and suggest that TSLP may act directly on sensory neurons.
Previous studies have shown that intradermal injection of the TRPV1 agonist, resiniferatoxin (RTX), results in ablation of primary afferent sensory neurons that express TRPV1, or TRPV1 and TRPA1 and consequently eliminates pain and itch behaviors (Imamachi et al., 2009; Mitchell et al., 2010) . TSLPevoked scratching was significantly decreased in RTX-treated mice as compared to control mice ( Figure 1F ). These findings show that the AD cytokine, TSLP, induces itch via sensory neurons.
TSLP Directly Activates an Uncharacterized Subset of Sensory Neurons
We next asked whether TSLPRs are expressed in sensory neurons. DRG neurons are a heterogeneous population of cells, including a subset of small-diameter, peripherin-positive neurons that transmit itch and pain signals to the CNS, and release inflammatory mediators in the skin and other target organs . We thus examined the prevalence of TSLPRpositive neurons and colocalization with known neuronal markers. In situ hybridization revealed that TSLPR and IL7Ra were expressed in a subset of small diameter DRG neurons (Figure 2A) . Using antibodies against TSLPR, we observed TSLPR protein expression in 5.9% of cells in DRG sections ( Figure 2B ). Costaining of TSLPR and peripherin, a marker of small-diameter DRG neurons, demonstrated that all TSLPR-positive neurons are also peripherin-positive, with an average diameter of 18.1 ± 0.6 mm ( Figure 2B ). Overall, the characteristics of TSLPR-positive neurons match those of sensory neurons that mediate itch and/ or pain (McCoy et al., 2013) .
If TSLPRs mediate somatosensory transduction, they should localize to primary afferent nerve terminals in the skin. We thus performed immunohistochemistry with antibodies against TSLPR and the pan-neuronal fiber marker PGP9.5 on mouse skin ( Figure 2C ). We observed TSLPR staining in 9% of PGP9.5-positive free nerve endings in the skin ( Figure 2C ). These data show that TSLPRs are localized to sensory neuronal endings that innervate the skin in close apposition to keratinocytes in the epidermis. Taken together, these data demonstrate that the TSLPR subunits are expressed in a subset of sensory neurons that innervate the skin and mediate itch and/or pain transduction.
To test whether TSLPR is functional in sensory neurons, we used ratiometric Ca 2+ imaging ( Figures 3A and 3B ). We found that 4.1% ± 0.6% of DRG neurons showed robust increases in intracellular Ca 2+ following TSLP application ( Figure 3E ); this is similar to the percentage of neurons that respond to other endogenous pruritogens, like BAM8-22 Wilson et al., 2011) . Previous studies have shown that small diameter sensory neurons transduce itch and/or pain signals via the ion channels TRPA1 and TRPV1 Ross, 2011) . Indeed, subsequent exposure to the TRPA1 agonist, allyl isothiocyanate (AITC), or the TRPV1 agonist, capsaicin (CAP), further increased Ca 2+ levels in all TSLP-positive cells ( Figures  3A and 3B) . Similarly, TSLP triggered action-potential firing in a subset of CAP-sensitive neurons ( Figure 3C ). These data suggest that TSLP activates a subset of TRPV1-and TRPA1-positive sensory neurons. The itch compounds histamine, chloroquine (CQ), and BAM8-22 have been shown to activate 5%-20% of sensory neurons (Ikoma et al., 2006; Imamachi et al., 2009; Liu et al., 2009; Wilson et al., 2011 ) that express TRPA1 and/or TRPV1. TSLP appears to activate an undescribed subset of itch neurons, as most TSLP-positive neurons were insensitive to other itch compounds ( Figures 3A, 3B , and 3D).
TSLPR and TRPA1 Mediate TSLP-Evoked Neuronal Activation
To ask whether TSLPRs mediate TSLP-evoked neuronal activation, we examined TSLP-evoked Ca 2+ signals in neurons isolated from IL7Ra-deficient mice. TSLP-, but not AITC-or CAP-evoked Ca 2+ signaling, was abolished in IL7a-deficient neurons (Figure 3E ). These results are consistent with previous studies in immune cells showing that functional IL7Ra is required for TSLP signaling (Pandey et al., 2000) . Here, we show that functional TSLPRs are required for TSLP-evoked neuronal activation. TRPV1 and TRPA1 channels are required for acute itch signaling and behavior (Ross, 2011) . We thus asked whether these channels are required for TSLP-evoked neuronal activation. TRPV1 and TRPA1 inhibition by the nonselective inhibitor, ruthenium red, significantly decreased neuronal sensitivity to TSLP ( Figure 3E ). We also compared neurons isolated from TRPA1-and TRPV1-deficient mice to those from wild-type littermates. TSLP-evoked Ca 2+ signals were significantly attenuated in TRPA1-deficient neurons, but not TRPV1-deficient neurons ( Figure 3E ). Our results show that TRPA1 channels mediate TSLP-evoked neuronal excitability. We next examined the mechanisms by which TSLPR activation promotes TRPA1 activity. Two signaling pathways have linked itch receptors to TRPA1 activation: phospholipase C (PLC) signaling couples MrgprC11 to TRPA1; and, Gbg signaling couples MrgprA3 to TRPA1 (Wilson et al., 2011) . Treatment of cells with the PLC inhibitor, U73122, significantly reduced the prevalence of TSLP-sensitive neurons ( Figure 3F ). In contrast, gallein, a Gbg inhibitor, had no effect on TSLP-evoked Ca 2+ signals ( Figure 3F ). Consistent with TSLP activation of the PLC pathway, TSLP triggers both release of Ca 2+ from intracellular stores and subsequent Ca 2+ influx in sensory neurons ( Figure 3G ). Overall, these experiments suggest that TSLPR and TRPA1 communicate via PLC signaling.
TSLPR and TRPA1 Mediate TSLP-Evoked Itch
To test whether TSLP and TRPA1 receptors are required for TSLP-evoked itch behaviors, we used the cheek model of itch. TSLP-evoked scratching was significantly attenuated in IL7Ra-deficient mice, supporting a role for TSLPRs in TSLP itch signaling ( Figure 4A ). These mice were not generally deficient in itch behaviors, as CQ-evoked scratching, which occurs via MrgprA3 , was normal ( Figure 4B ). These data demonstrate that TSLP targets TSLPRs to trigger itch behaviors in vivo.
We next asked whether TSLP-evoked itch behaviors require TRP channels. TSLP-evoked scratching was abolished in TRPA1-deficient mice, but normal in TRPV1-deficient mice (Figure 4D) . These experiments show that both functional TSLPRs and TRPA1 channels are required for TSLP-evoked itch. PLC signaling is also required for the functional coupling between TSLPR and TRPA1 in vivo, as TSLP-evoked scratching was significantly attenuated by intradermal injection of U73122. Such treatment selectively silenced TSLP-evoked behaviors, as these mice displayed normal CQ-evoked scratching, which is PLC-independent (Wilson et al., 2011) . Overall, these data demonstrate a role for TSLP as a pruritogen and a robust activator of sensory neurons and suggest that these neurons may contribute to the initiation of TSLP-evoked inflammatory responses in the skin in AD and airways in asthma.
Keratinocyte Release of TSLP Is Ca 2+ Dependent
Our data establish a cellular target for TSLP, supporting a model whereby both immune cells and sensory neurons are activated by keratinocyte-derived TSLP to drive itch and AD. What are the upstream mechanisms that govern the expression and release of TSLP by keratinocytes? Protease signaling via PAR2 plays a key role in TSLP production and AD. PAR2 activity, and levels of the endogenous PAR2 agonist, tryptase, are increased in the skin of AD patients . Consistent with a previous study (Ui et al., 2006) , injection of tryptase induced robust itch behaviors in mice ( Figure 5A ). Tryptase-evoked itch was significantly attenuated in both PAR2-and IL7Ra-deficient mice ( Figure 5A ), consistent with a pathway where PAR2 signaling promotes the release of TSLP from keratinocytes, which then acts on TSLPR-positive neurons to drive itch behaviors. We next sought to determine the signaling pathways that control PAR2-induced TSLP expression in keratinocytes. Studies on keratinocytes have shown that the endogenous PAR2 agonist, tryptase, and the widely used PAR2 ligand mimetic, Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL), elicits Ca 2+ influx (Schechter et al., 1998; Zhu et al., 2009 ) and triggers the Ca
2+
-dependent release of inflammatory mediators (Halfter et al., 2005; Santulli et al., 1995; Schechter et al., 1998) . For example, SLIGRL triggers a rise in intracellular Ca 2+ in keratinocytes (Zhu et al., 2009 ) and also promotes TSLP expression (Moniaga et al., 2013) . We thus asked if PAR2-evoked TSLP expression is Ca 2+ -dependent. ELISA measurements revealed that treatment of keratinocytes with tryptase or SLIGRL, but not vehicle, triggered the robust secretion of TSLP ( Figure 5B ). These data show that PAR2 stimulation of keratinocytes triggers TSLP release. TSLP secretion was highly dependent on Ca
. First, TSLP secretion was not observed in keratinocytes treated with tryptase or SLIGRL in the absence of external Ca 2+ ( Figure 5B ). In addition, treatment with the drug thapsigargin (TG), which promotes depletion of intracellular Ca 2+ stores and subsequent Ca 2+ influx, caused a significant increase in TSLP secretion ( Figure 5B ). These data demonstrate that Ca 2+ is required and sufficient to drive TSLP secretion.
A recent study has shown that some PAR2 agonists, including SLIGRL, also activate the sensory neuron-specific itch receptor, MrgprC11 (MrgprX1 in human) . However, this result does not impact our in vitro studies for several reasons. First, keratinocytes do not express MrgprX1 ( Figure S1A available online) . Second, keratinocytes are insensitive to the MrgprX1-specific ligand, BAM8-22 (Figure S1B) . Third, tryptase-evoked itch is dependent on PAR2 ( Figure 5A ). Finally, tryptase does not activate MrgprC11 in mice ( Figures S1C-S1D) Figures 6A and 6B) .
What are the molecules mediating PAR2-evoked SOCE in keratinocytes? Both ORAI and TRPC channels have been implicated in SOCE (Cahalan, 2009; Ramsey et al., 2006) . We next asked whether PAR2 activates SOCE via ORAI or TRPC channels, which can be distinguished by their distinct pharmacological profiles (DeHaven et al., 2008; Lis et al., 2007; Zhang et al., 2008 . These data show that tryptase and SLIGRL activate the same SOCE pathway and support a role for ORAI channels in PAR2-evoked SOCE ( Figure 6C ).
ORAI and TRPC channels can also be distinguished by their distinct biophysical characteristics: ORAI1 and ORAI2 are Ca 2+ -selective channels that are inwardly-rectifying, whereas TRPC channels are outwardly-rectifying, nonselective channels (Cahalan, 2009; Owsianik et al., 2006; Yeromin et al., 2006) . Thus, we measured SLIGRL-evoked currents using perforatedpatch, voltage-clamp recordings on keratinocytes. Treatment with SLIGRL triggered an ORAI1/2-like current; the currents were dependent on extracellular Ca 2+ , displayed an inwardlyrectifying current-voltage relationship, and displayed no measurable reversal potentials below +80 mV ( Figure 6D ). These results implicate ORAI1 and/or ORAI2 in PAR2-evoked SOCE. Quantitative PCR demonstrated that keratinocytes express ORAI1, ORAI2, and the ORAI regulator, stromal interaction molecule 1 (STIM1). We thus examined the role of ORAI1, ORAI2, and STIM1 in SOCE using siRNA-mediated knockdown. Depletion of ORAI1 transcripts by 71% or STIM1 transcripts by 84% significantly diminished Ca 2+ entry in response to SLIGRL as compared to scrambled control siRNA ( Figures 6E-6G ). ORAI1 and STIM1 knockdown also significantly attenuated tryptaseevoked Ca 2+ signals (data not shown). In contrast, depletion of ORAI2 transcripts by 86% had no effect on SLIGRL-evoked SOCE ( Figures 6E and 6G ). These data demonstrate that ORAI1 and STIM1 are required for PAR2-evoked SOCE in human keratinocytes. ORAI1 and STIM1 knockdown also attenuated TG-evoked SOCE ( Figure 6G ), suggesting that ORAI1 is the primary store-operated Ca 2+ pathway in keratinocytes.
PAR2-Activation Induces Ca 2+ -Dependent NFAT Translocation and TSLP Secretion
In immune cells, ORAI1 signaling activates NFAT, which triggers cytokine expression and secretion Gwack et al., 2007) . The ORAI1/NFAT pathway may play a similar role in keratinocytes, promoting the expression and secretion of TSLP. Consistent with a regulatory role for NFAT in TSLP expression, two NFAT binding motifs (GGAAAATN) (Rao et al., 1997; Zhu et al., 2009 ) are present in the 5 0 -upstream regulatory region of the human TSLP gene. These findings imply that PAR2 may trigger NFAT-dependent expression and release of TSLP; however, the evidence is merely correlative. To directly test this hypothesis, we measured PAR2-dependent NFAT translocation and TSLP expression and release in keratinocytes.
Following a rise in Ca 2+ , NFAT is dephosphorylated by the Ca 2+ -dependent phosphatase calcineurin and translocates from the cytosol to the nucleus to promote transcription of target genes (Rao et al., 1997) . Immunostaining demonstrated that treatment of keratinocytes with SLIGRL for 30 min induced robust NFAT translocation to the nucleus (Figures 7A). This translocation was attenuated by blocking ORAI channels with 2-APB, or by inhibiting NFAT activity with cyclosporine A (CsA), an inhibitor of calcineurin ( Figure 7A) ; similar results were observed using live cell imaging of a human keratinocyte cell line, HaCat, that expressed NFAT-GFP ( Figure 7B ). These results show that PAR2 activation induces Ca 2+ -dependent NFAT translocation, which may lead to NFAT-dependent changes in gene expression. In support of this model, PAR2-evoked SOCE robustly increased expression of TSLP transcripts in keratinocytes ( Figure 7C ). We next addressed whether ORAI1/NFAT signaling mediates PAR2-evoked TSLP release. We found that siRNA-mediated knockdown of ORAI1 or STIM1 significantly attenuated SLIGRL-evoked TSLP release by keratinocytes, suggesting that ORAI1 is required for PAR2-evoked TSLP secretion (Figure 7D) . Likewise, inhibition of NFAT-mediated transcription with CsA also attenuated TSLP release ( Figure 7E ), but had no effect on SOCE-evoked Ca 2+ signals (data not shown). In addition to cutaneous epithelial cells, airway epithelial cells of patients with allergic rhinitis, AD and asthma also display high TSLP expression (Ziegler et al., 2013) . Previous studies have shown that TG induces ORAI1-dependent Ca 2+ signals in human airway epithelial cells (Gusarova et al., 2011) . Interestingly, we found that, like keratinocytes, SOCE triggers robust TSLP expression in human airway epithelial cells, which can be blocked by CsA (data not shown). These data identify ORAI1-dependent NFAT activation as a regulator of TSLP expression and release in both cutaneous and airway epithelial cells.
We next tested the hypothesis that NFAT promotes TSLP expression in vivo. Mice were treated with SLIGRL, SLIGRL and CSA, or vehicle via intradermal injection into the back. TSLP protein levels in treated skin were measured 3 hr after injection. Coinjection of CsA significantly attenuated SLIGRL-evoked TSLP protein expression in skin ( Figure 7F ). Similar results were also observed with the endogenous PAR2 agonist, tryptase ( Figure 7G ), demonstrating that PAR2 triggers TSLP expression via the Ca 2+ -calmodulin/NFAT pathway in vivo.
DISCUSSION
TSLP plays a key role in the triad of atopic diseases: asthma, allergic rhinitis, and atopic dermatitis (Ziegler et al., 2013) . Recent studies have also implicated TSLP in a number of disorders, including cancer, gastrointestinal diseases, and autoimmunity (Ziegler et al., 2013) . As such, there is much interest in understanding the mechanisms of TSLP expression and downstream effects of TSLP secretion. Here, we present molecular, cellular, and behavioral data showing that ORAI1/NFAT signaling regulates TSLP release by keratinocytes and that TRPA1 is required for TSLP-evoked activation of sensory neurons and subsequent itch behaviors. Our data support a model whereby TSLP released from keratinocytes acts directly on sensory neurons to trigger robust itch-evoked scratching ( Figure 7H ).
Sensory Neurons Mediate TSLP-Evoked Itch
Studies on the role of TSLP in promoting atopic disease have focused solely on its effects on immune cells. A variety of immune cells are activated by TSLP, including dendritic cells, T cells, B cells, natural killer cells, mast cells, basophils, and eosinophils, which together promote allergic inflammation (Ziegler et al., 2013) . The inflammatory cytokines produced by these immune cells can activate sensory neurons (Cevikbas et al., 2007) . TSLP expression in keratinocytes leads to robust scratching in mice, which was previously assumed to occur solely downstream of immune cell cytokine release (Bogiatzi et al., 2012; Yoo et al., 2005) . The current model is that sensory neurons are activated downstream of TSLP-activated immune cells to induce itch. Our data support the direct activation of sensory neurons by TSLP. First, we show that mast cell release of histamine, or other pruritogens, is not required for TSLP-evoked itch behaviors. In addition, histamine-dependent itch requires TRPV1 (Imamachi et al., 2009) , and our data show that TRPV1-deficient mice display normal TSLP-evoked itch behaviors. Finally, we show that acute TSLP-evoked itch does not require lymphocytes. These results were surprising given the well-known role of immune cells in TSLP-evoked atopic disease. However, until now, studies have focused on the long-term, rather than the acute effects of TSLP. These data suggest that the acute versus chronic phases of TSLP-evoked inflammation may be mediated by distinct mechanisms. In addition, because activation of primary afferent neurons triggers the release of inflammatory agents that promote immune cell chemoattraction and activation (e.g., substance P) (Basbaum et al., 2009 ), neuron-to-immune cell activates the phosphatase calcineurin, which dephosphorylates NFAT and causes nuclear translocation, thus inducing transcription of TSLP. Secreted TSLP depolarizes a subset of C-fibers to evoke itch, in a TSLPR-and TRPA1-dependent manner. Activation of TRPA1-expressing sensory neurons can then lead to release of neuropeptides in the skin in a process known as neurogenic inflammation.
communication may also play a key role in the development of AD. Thus far, all published studies have focused on global knockouts of TSLPR. Future studies using tissue-specific TSLPR knockout mice are required to determine the relative contributions of sensory neurons and immune cells to both the acute and chronic phases of AD.
TRPA1 Is Required for TSLP-Evoked Itch TSLP activates a subset of sensory neurons that express TSLPRs and the irritant receptor TRPA1. TRPA1-positive sensory neurons are required for the transmission of itch and pain stimuli to the CNS Ross, 2011) . Recent studies have shown that TRPA1 is also required for dry skinand allergen-evoked chronic itch (Liu et al., 2013; Wilson et al., 2013) , but the endogenous signaling molecules that promote TRPA1 activation in these itch models are unknown. We now show that the endogenous AD cytokine, TSLP, leads to TRPA1 activation, downstream of TSLPR. Inhibition of PLC significantly attenuates such coupling both in vitro and in vivo. Despite the extensive literature on TSLP in immune cells, little is known about the signaling pathways activated downstream of TSLPR. The JAK/STAT pathway has been implicated in TSLP signaling but thus far, neither TSLPR nor IL7R have been linked to PLC (Ziegler et al., 2013) .
TRPA1 afferents are not restricted to the skin, but also densely innervate the airways and gastrointestinal tract . Indeed, TRPA1 activation promotes lung inflammation in mouse models of airway inflammation and asthma and triggers inflammation in mouse models of inflammatory bowel disease . Interestingly, we found that like keratinocytes, Ca 2+ signaling through ORAI1 triggers robust TSLP expression in human airway epithelial cells (data not shown). Thus, crosstalk between sensory neurons and epithelial cells via TSLP and TRPA1 may not be restricted to the skin, but may also occur in the airways and gut. The ''atopic march'' has been largely attributed to the actions of epithelial and immune cells (Holgate, 2007) . Future studies using tissue-specific TSLPR-deficient animals are required to resolve the contributions of neuronal and immune cell TSLP signaling to atopic disease. Nonetheless, our findings highlight a potential new role for TRPA1 and sensory neurons in promoting the atopic march.
ORAI1/NFAT Regulates TSLP Release in Keratinocytes ORAI1 was first identified as the channel that mediates storeoperated Ca 2+ influx required for NFAT-dependent cytokine expression during immune cell activation; loss of function mutations in ORAI1 and STIM1 lead to severe combined immunodeficiencies in patients (Feske, 2010; Feske et al., 2006; Prakriya et al., 2006; Yeromin et al., 2006) . Our work shows that in addition to lymphocytes, epithelial cells also utilize ORAI1-mediated Ca 2+ influx to regulate cytokine expression and release, suggesting that ORAI1 plays a more general role in the pathogenesis of inflammatory disease. Thus, ORAI1 may represent a new therapeutic target for atopic disease. A role for the ORAI1/NFAT pathway in AD is consistent with a number of disparate clinical findings. First, SNPs in the ORAI1 gene have been linked to susceptibility to atopic disease in humans (Chang et al., 2012) but the role of ORAI1 in AD had not been studied. Second, NFAT displays an abnormally high degree of nuclear localization in the keratinocytes of chronic itch patients (Al-Daraji et al., 2002) , but the consequences of NFAT activation on AD was unknown. Finally, CsA, an inhibitor of NFAT-mediated transcription, is a potent immunosuppressant drug and is often prescribed for itchy inflammatory skin diseases, such as psoriasis and AD (Madan and Griffiths, 2007) . Although its effects have been mainly attributed to immune cell inhibition, our work suggests that the effectiveness of CsA in treating chronic itch may, in part, be due to its effects on keratinocyte-mediated TSLP release.
EXPERIMENTAL PROCEDURES
Cell Culture Primary human epidermal keratinocytes (PromoCell) and HaCaT cells were cultured in PromoCell Keratinocyte Medium 2 and DMEM, respectively. siRNA directed against ORAI1, ORAI2, and STIM1 (QIAGEN; 100 ng) were transfected using HiPerFect (QIAGEN). HaCaT cells were transiently transfected with Lipofectamine 2000 (Invitrogen) using 1 mg HA-NFAT1(1-460)-GFP plasmid (Addgene 11107). DRG neurons were isolated from P18-30 mice and cultured as previously described (Wilson et al., 2011) . All media and cell culture supplements were purchased from the UCSF Cell Culture Facility.
Ca
2+ Imaging
Ca 2+ imaging was carried out as previously described (Wilson et al., 2011) .
Physiological Ringer solution: 140 mM NaCl, 5 mM KCl, 10 mM HEPES, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM D-(+)-glucose, and pH 7.4 with NaOH. Images were collected and analyzed using MetaFluor (Molecular Devices).
[Ca 2+ ] i was determined from background-corrected F 340 /F 380 ratio images using the relation [Ca 2+ ] I = K*(R À R min )/(R max À R) (Almers and Neher, 1985) , with the following parameters measured in keratinocytes: R min = 0.3; R max = 2.2; and K* = 3 mM. Cells were classified as responders if [Ca 2+ ] i increased 15% above baseline.
Electrophysiology
Recordings were collected at 5 kHz and filtered at 2 kHz using an Axopatch 200B and PClamp software. Electrode resistances were 2-6 MU. Perforated patch internal solution: 140 mM CsCl, 5 mM EGTA, 10 mM HEPES, pH 7.4 with CsOH, and 0.24 mg ml À1 Amphotericin B (Rae et al., 1991) . Stimulation protocol: 10 ms step to À80 mV, 150 ms ramp from À80 mV to +80 mV. Current clamp internal solution: 140 mM KCl, 5 mM EGTA, and 10 mM HEPES (pH 7.4 with KOH). Series resistance of all cells were <30 MU and liquid junction potentials were <5 mV (no correction).
RT-PCR
RNA was extracted using RNeasy (QIAGEN) and reverse transcription was performed using Superscript III. RT-PCR was carried out using SYBR Green (Invitrogen) on a StepOnePlus ABI machine. Threshold cycles for each transcript (Bogiatzi et al., 2012) were normalized to GAPDH (DC t ). Calibrations and normalizations used the 2 ÀDDCt method where DDC t = [(C t (target gene) À C t (reference gene)] À [C t (calibrator) À C t (reference gene)]; GAPDH = reference gene; scrambled siRNA = calibrator. Experiments were performed in triplicate.
Histology
Histology was carried out as previously described (Gerhold et al., 2013) . Antibodies: rabbit anti-PGP9.5 and rabbit anti-peripherin (Millipore) 1:1,000; goat anti-TSLPR and mouse anti-NFATc1 (Santa Cruz Biotechnology) 1:100. IL7Ra and TSLPR probes (Panomics) were used for in situ hybridization following the Quantigene protocol (Panomics).
Protein Detection TSLP protein levels were measured using the DuoSet ELISA kit (R&D Systems) on media collected 24 hr after stimulation. TSLP release was normalized to vehicle. For western blots, 50 mg of cleared tissue lysate was resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with anti-TSLP (1:250, Genetex), anti-Calnexin (1:2,000, Abcam), and anti-Actin (1:2,000).
Mice and Behavior
Mice (20-35 g) were housed in 12 hr light-dark cycle at 21 C. Behavioral measurements were performed as previously described (Wilson et al., 2011) . Compounds injected: 2.5 mg TSLP, 200 mg CQ, 100 pg tryptase dissolved in PBS, or RTX 1 mg/ml in 0.05% ascorbic acid and 7% Tween 80 (2 days prior to pruritogen injection). For AITC behavior, 5 ml 10% AITC in mineral oil was applied to the right hind paw. Behavioral scoring was performed while blind to treatment and genotype. All experiments were performed under the policies and recommendations of the International Association for the Study of Pain and approved by the University of California, Berkeley Animal Care and Use Committee.
Data Analysis
Data are shown as mean ± SEM. Statistical significance was evaluated using a one-way ANOVA followed by a Tukey-Kramer post hoc test or unpaired twotailed Student's t test for comparing difference between two samples (*p < 0.05, **p < 0.01, ***p < 0.001).
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